{"title":"Rasagiline hemitartrate: Synthesis, characterization and RP-HPLC validation for its estimation in bulk form","authors":"Muvvala S. Sudhir , Ratnakaram Venkata Nadh","doi":"10.1016/j.dit.2013.05.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To develop a reverse phase high performance liquid chromatographic method for validation and quantitative estimation of the synthesized drug rasagiline hemitartrate in bulk form.</p></div><div><h3>Methods</h3><p>Rasagiline hemitartrate was synthesized and characterized by spectral (Infrared, Proton Nuclear Magnetic Resonance and Mass) as well as elemental analysis. Chromatographic separation was conducted on Agilent TC-C18 (250 × 4.6 mm, 5 μm) column at ambient temperature using mixture of 20 mM potassium dihydrogen orthophosphate buffer (pH 7.0): methanol and acetonitrile in the ratio (30:30:40 v/v) as a mobile phase and at a flow rate of 1.0 mL/min, while UV detection was performed at 285 nm. In addition to LOD and LOQ, other analytical parameters viz., linearity, precision, accuracy, ruggedness and robustness were detected by following the ICH (International Conference on Harmonization) guidelines.</p></div><div><h3>Results</h3><p>The retention time for rasagiline hemitartrate was found to be 4.30 ± 0.05 min. The method was found to be linear in the range of 10–50 μg/mL. The limit of detection and quantization for rasagiline hemitartrate are found to be 0.651 and 1.972 μg/mL respectively. Analytical recovery was 100.47%. The percentage RSD for precision and accuracy of the method was found to be less than 2%. Correlation coefficient was found to be 0.9952.</p></div><div><h3>Conclusion</h3><p>In this study, simple, sensitive, accurate and reliable RP-HPLC method was developed and validated as per the ICH guidelines for the determination of the synthesized drug rasagiline hemitartrate in bulk form.</p></div>","PeriodicalId":11284,"journal":{"name":"Drug Invention Today","volume":"5 2","pages":"Pages 133-138"},"PeriodicalIF":0.0000,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dit.2013.05.002","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Invention Today","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0975761913000288","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
Abstract
Objectives
To develop a reverse phase high performance liquid chromatographic method for validation and quantitative estimation of the synthesized drug rasagiline hemitartrate in bulk form.
Methods
Rasagiline hemitartrate was synthesized and characterized by spectral (Infrared, Proton Nuclear Magnetic Resonance and Mass) as well as elemental analysis. Chromatographic separation was conducted on Agilent TC-C18 (250 × 4.6 mm, 5 μm) column at ambient temperature using mixture of 20 mM potassium dihydrogen orthophosphate buffer (pH 7.0): methanol and acetonitrile in the ratio (30:30:40 v/v) as a mobile phase and at a flow rate of 1.0 mL/min, while UV detection was performed at 285 nm. In addition to LOD and LOQ, other analytical parameters viz., linearity, precision, accuracy, ruggedness and robustness were detected by following the ICH (International Conference on Harmonization) guidelines.
Results
The retention time for rasagiline hemitartrate was found to be 4.30 ± 0.05 min. The method was found to be linear in the range of 10–50 μg/mL. The limit of detection and quantization for rasagiline hemitartrate are found to be 0.651 and 1.972 μg/mL respectively. Analytical recovery was 100.47%. The percentage RSD for precision and accuracy of the method was found to be less than 2%. Correlation coefficient was found to be 0.9952.
Conclusion
In this study, simple, sensitive, accurate and reliable RP-HPLC method was developed and validated as per the ICH guidelines for the determination of the synthesized drug rasagiline hemitartrate in bulk form.